Searchable abstracts of presentations at key conferences in endocrinology

ea0007oc27 | Endocrine tumours | BES2004

Gamma knife sterotactic radiosurgery for acromegaly

Nawaz A , Newton D , Sandeman D , Rowe J , Ross R , Kemeny A , Newell-Price J

Background: Gamma-Knife Stereotactic Radiosurgery (STRS) is a single highly focused dose of radiotherapy used for intracranial pathologies, including pituitary tumours. At the National Centre for Stereotactic Radiosurgery in Sheffield more than 450 patients undergo STRS per year. The UK experience of this modality of treatment for acromegaly is limited because of the few gamma knife units in operation.Objective: To assess the effectiveness and safety of ...

ea0007oc28 | Endocrine tumours | BES2004

Biochemical and genetic screening in isolated and familial MEN1

Lee S , Roper E , Kirk R , Howie H , Doane A , Quarrell O , Harrison B , Ross R

Background: Multiple endocrine neoplasia type 1 (MEN1) is an inherited cancer syndrome characterized by the development of tumours in at least two of the following three main sites: parathyroid, pituitary and endocrine pancreas. Hyperparathyroidism is the most common presenting feature, with a typical age at onset of 20-25 years, and > 90% penetrance by 40 years. After extended family studies, an index case may have no affected relatives and be apparently 'isolated'. We rep...

ea0007p155 | Neuroendocrinology and behaviour | BES2004

The effect of oestrogen replacement therapy (ORT) on growth hormone (GH) dose; KIMS database perspective

Mah P , Ross R , Jonsson P , Feldt-Rasmussen U , Koltowska-Haggstrom M , Webster J

Oral but not transdermal ORT reduces serum IGF-1 levels in postmenopausal women. The effect of ORT type on GH dose and sensitivity is unclear. We present a retrospective analysis of GH-deficient women on ORT in the KIMS database.AIM: To determine the type of oestrogen prescribed and its effect on GH dose.METHOD: Patients were divided into groups taking oral oestradiol valerate, conjugated oestrogen, ethinyloestradiol and transderma...

ea0006s24 | Steroid replacement | SFE2003

A Simplfied Protocol for Hydrocortisone Replacement Therapy in Patients with Adrenal Insufficiency

Mah P , Jenkins R , Rostami-Hodjegan A , Newell-Price J , Doane A , Ibbotson V , Tucket G , Ross R

Background. Adrenal insufficiency requires life long corticosteroid therapy, but optimal dosing of hydrocortisone replacement has not received adequate attention.Chronic over or under treatment predisposes to morbidity and mortality.Objective.To examine the variables determiming hydrocortisone disposition and develop practical protocols for individualised prescribing and monitoring of treatment.Design. Prospective open study.<p...

ea0005p76 | Cytokines and Growth Factors | BES2003

Development of a bioassay for leptin agonists and antagonists

Fazeli M , Zarkesh-Esfahani H , Maamra M , Justice S , Ross R

Introduction: Identifying leptin agonists and antagonists requires a reliable bioassay responsive to physiological levels of leptin. The leptin receptor exists in multiple isoforms but Ob-Rb, the full length receptor, mediates the biological actions of leptin and its predominant signalling pathway is through STAT3. We report the development of a bioassay based on a STAT3 firefly luciferase reporter. Materials and Methods: HEK 293 cells were transfected with varying amounts of ...

ea0005p185 | Neuroendocrinology and Behaviour | BES2003

Abnormal endocrine tests in chronic pain require investigation and are not the result of opioid analgesia

Merza Z , Edwards N , Walters S , Newell-Price J , Ross R

Background: Anecdotally patients with chronic pain on opioid analgesia have functional hypopituitarism, and studies in opioid addicts show suppressed pituitary function. We conducted a prospective observational study to determine the endocrine status of patients with chronic pain on opioid analgesia. Methods: 37 consecutive patients with chronic back pain attending the pain clinic were enrolled. 22 patients (age 45+/-9 years) were on long-term opioid analgesia and 15 (age 53 +...

ea0005p208 | Reproduction | BES2003

Pharmacokinetics and tolerability of a new a bioadhesive buccal testosterone tablet in testosterone deficient men

Ross R , Jabbar A , Jones H , Roberts B , Dunkley K , Long A , Levine H , Cullen D

Pharmacokinetics and tolerability of a new a bioadhesive buccal testosterone tablet in testosterone deficient men.RJM Ross, A Jabbar, H Jones, B Roberts, K Dunkley, A Long, H Levine, DR CullenObjectives: A phase I single centre, open label study of the pharmacokinetics and tolerability of a buccal testosterone tablet (COL1621). Design: The study was approved by The South Sheffield Ethics Committee. Twelve testosterone deficient males were treated with the buccal tablet...

ea0003oc32 | Metabolism | BES2002

Regulation of leptin receptor cleavage

Maamra M , Bidlingmaier M , Postel-Vinay M , Wu Z , Strasburger C , Ross R

The leptin receptor (ObR) exists in multiple isoforms. In humans, there is no mRNA encoding soluble receptor (LBP). We investigated the hypothesis that human LBP can be generated by proteolytic cleavage of membrane anchored leptin receptors (ObRb and ObRa). LBP, of similar size to that previously detected in human serum, was detected in medium of cells transfected with ObRa by HPLC, Immunofluorometric assay, and Ligand mediated immunofluorometric assay, but not by ELISA. The L...

ea0003p78 | Cytokines and Growth Factors | BES2002

Leptin increases expression of CD11b on human neutrophils

Zarkesh-Esfahani S , Pockley G , Norman K , Metcalfe R , Aylott C , Hellewell P , Weetman A , Ross R

Background: Leptin is a multi-functional hormone of which low levels are associated with immuno-deficiency. We and others have shown that leptin promotes secretion of inflammatory cytokines (TNF-alpha and IL-6) by monocytes (1) and activated lymphocytes (2). The leptin receptor (Ob-R) is expressed on neutrophils and leptin enhances oxidative species production by stimulated neutrophils.Aim: To access whether CD11b expression on human neutrophils is a di...

ea0003p177 | Neuroendocrinology | BES2002

Growth hormone deficient patients over 60 years require a low dose of GH and short titration phase to achieve normal serum IGF-I levels

Mah P , Newell-Price J , Doane A , Ibbotson V , Ho K , Ross R

AIM: 1) To determine GH dose requirement in GH deficient patients aged over 60 years. METHODS: The study was approved by the local Ethics Committee. Patients were started on Genotropin 0.4 units (0.13 mg)/day after baseline assessment. Serum IGF-I was repeated at 2-weekly intervals. Maintenance GH dose was achieved when serum IGF-1 was between the median and upper end of the age-related range. RESULTS: 16 patients (10 men & 6 women) were recruited. Their median (range) age...